Trial Profile
Interest of a High Dose of Erythropoietin Administered During Graft Processing for Early Graft Outcome in Kidney Transplant Recipients.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erythropoietin (Primary)
- Indications Transplant rejection
- Focus Therapeutic Use
- Acronyms FRETEP
- 16 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Dec 2011 Actual initiation date (Dec 2011) added as reported by ClinicalTrials.gov.
- 21 Dec 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.